Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Inclusion Criteria: * The participant has histologically documented advanced or metastatic malignant cancer of solid tumor origin which has not responded to standard therapy or for which no standard therapy is available * The participant has resolution of adverse events from prior anticancer therapies * Performance status of 0 to 2 * The participant is ≥ 18 years of age * The participant is able to provide informed written consent and is amenable to compliance with protocol schedules and testing * The participant has adequate liver, kidney, blood, and blood clotting functions as defined in trial entrance criteria * The participant agrees to use adequate contraception during the study period and for 8 weeks after the last dose of study treatment Exclusion Criteria: * The participant had anticancer therapy within 14 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study * The participant had therapeutic radiotherapy within 14 days prior to entering the study * The participant has ongoing side effects ≥ Grade 2 due to prior anticancer therapy * The participant has brain or leptomeningeal metastases * The participant has a history of uncontrolled or severe cardiac disease * The participant has a history of severe congestive heart failure (CHF) * The participant has a known history of arterial thrombotic events * The participant has a known history of significant peripheral arterial disease (PAD) * The participant has an implantable pacemaker or automatic im…